MK-677 (Ibutamoren) / Research reference
MK-677 is ibutamoren, a non-peptide small molecule studied as a growth hormone secretagogue. It activates the ghrelin receptor and has been investigated in several human populations. Its literature illustrates an important distinction: changing growth hormone or IGF-1 does not necessarily improve strength, function, or disease outcomes. This profile concerns ibutamoren specifically; the separate catalog name MK777 is not treated as its synonym.
Human trials and receptor researchA focused reference from the Disguised Alpha research network.
Disguised Alpha catalog
Open the exact product listing for its format and documentation. Published studies do not validate a supplier’s finished product.
01 / The science
Start with the mechanism, identify the experimental model, and keep the limits in view.
Structural research shows how ibutamoren binds the human ghrelin receptor, GHSR, and supports an active signaling complex. The molecule mimics aspects of ghrelin recognition despite having a different chemical structure. This receptor-level explanation does not establish the clinical value of any resulting hormone change.
Read the primary source ↗A trial in older adults measured hormone concentrations and body composition alongside strength and functional outcomes. Fat-free mass increased, but strength and function did not improve. These endpoints answer different questions; a body-composition change should not be described as a demonstrated improvement in physical performance.
Read the primary source ↗Trials in Alzheimer disease and hip-fracture recovery tested outcomes beyond hormone levels. The Alzheimer study found no slowing of progression. The hip-fracture trial ended early after a heart-failure safety signal. These findings belong alongside the mechanistic literature when assessing the research as a whole.
Read the primary source ↗02 / Read with context
Research findings apply to the exact compound, formulation, population and endpoints tested. They do not establish the identity, quality, clinical suitability or performance of a supplier’s product. This reference provides no dosing or administration guidance.
03 / Selected publications
Original records, study models and the limits that matter when interpreting a result.
Researchers resolved ibutamoren-bound receptor structures and tested residues involved in recognition and activation. The work connects molecular binding with receptor signaling.
Reading limit: A human protein studied in a laboratory is not a clinical trial. Structural activity cannot establish safety or functional benefit in people.
The study found increases in growth hormone, IGF-1, and fat-free mass without improved strength or function. Fasting glucose increased and insulin sensitivity decreased; appetite changes, edema, and muscle discomfort were also reported.
Reading limit: The small sample and study duration limited assessment of functional outcomes. The results do not establish an anti-aging or athletic-performance benefit.
IGF-1 increased, but the investigators found no significant treatment differences across the principal measures of cognition, daily function, or clinical progression over twelve months.
Reading limit: This is evidence in a specific clinical population. It demonstrates why target engagement cannot substitute for a meaningful outcome.
A focused selection, not a systematic review. Studies concern the tested material and do not validate a supplier’s finished product.
Explore research & source notes →04 / Common questions
Quick answers for reading the science behind MK-677 (Ibutamoren).
This page identifies MK-677 as ibutamoren. MK777 is a separate catalog designation, and the ibutamoren sources cited here do not establish equivalence. Names should be checked against exact chemical identity.
Neither. It is a non-peptide small molecule that activates the ghrelin receptor. A growth hormone secretagogue stimulates a signaling pathway; it is not growth hormone itself.
No. In the Alzheimer trial, IGF-1 rose without a corresponding improvement in the clinical endpoints. Biomarkers and outcomes must be evaluated separately.
Its early termination after a congestive-heart-failure signal is relevant safety evidence. It should remain visible even when other studies report hormone or body-composition changes.
Continue your research
Explore the complete MK-677 (Ibutamoren) profile and related compounds in the Disguised Peptides research hub.
